Global Blood Plasma Derivatives Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In June 2023: Grigols (Spain) Group and Canadian Plasma Resources sign a contract to guarantee the availability of plasma in Canada. Grifols and their agreement state that by 2026, Grifols will produce 2.4 million grams of Ig medications annually after progressively growing their Canadian plasma supply.
• In April 2023: Biotest AG (Germany) opens its 10th plasma collection centre in Germany. Biotest is thus continuing the planned expansion of its own donation centres in Europe to contribute to more plasma collection after the plasma shortage in Germany and Europe.

The global blood plasma derivatives market is segmented by product type into several categories, each experiencing varying degrees of growth. Immunoglobulins, one of the largest segments, are witnessing substantial demand due to their effectiveness in treating immune deficiencies and autoimmune diseases. The rising incidence of such conditions globally has spurred the need for these critical therapies. Coagulation factors, another significant segment, are primarily driven by the increasing prevalence of hemophilia and other bleeding disorders. Advances in recombinant technologies and improved manufacturing processes have further enhanced the availability and efficacy of these products. Albumin, used extensively in critical care settings for volume expansion and hypoalbuminemia, also constitutes a considerable market share, driven by its broad therapeutic applications.

From an application standpoint, the blood plasma derivatives market is broadly categorized into immunology, hematology, critical care, and others. The immunology segment dominates the market, propelled by the rising number of patients requiring immunoglobulin therapy for primary and secondary immunodeficiencies. Hematology applications, particularly for treating hemophilia and other clotting disorders, are experiencing robust growth due to increased diagnosis rates and the availability of advanced coagulation products. Critical care applications are expanding as plasma derivatives like albumin and clotting factors become integral in managing severe medical conditions and surgical interventions. Additionally, the growing use of plasma derivatives in treating neurological disorders and rare diseases is opening new avenues for market expansion.

The end-user segment analysis reveals that hospitals and clinics are the primary consumers of blood plasma derivatives, owing to their extensive use in treating a wide range of conditions and managing emergencies. The growing network of healthcare facilities, particularly in developing regions, is contributing to the increased uptake of these products. Additionally, blood donation centers and research institutes play a pivotal role in the supply chain, ensuring the steady availability of plasma for fractionation and the development of new therapies. The rising focus on homecare settings, facilitated by advancements in infusion technologies and patient preference for home-based treatments, is also emerging as a significant trend, influencing market dynamics.

North America holds a dominant position in the global blood plasma derivatives market, attributed to well-established healthcare infrastructure, high healthcare expenditure, and robust support for blood donation programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK, where there is a high prevalence of autoimmune and bleeding disorders. The Asia-Pacific region is poised for the fastest growth, driven by increasing healthcare awareness, rising disposable incomes, and government initiatives to improve healthcare access. Emerging markets in Latin America and the Middle East & Africa are also witnessing steady growth, supported by improving healthcare infrastructure and growing investments in medical research and development.

Global Blood Plasma Derivatives Segment Analysis

In this report, The Global Blood Plasma Derivatives Market Has Been Segmented By Type, Application and Geography.

Global Blood Plasma Derivatives Market, Segmentation by Type

The Global Blood Plasma Derivatives Market has been segmented by Type into FactorVIII Concentrate, FactorIX Concentrate, Albumin, ImmuneGlobulins, Anti-Thrombin III Concentrate, Fresh Frozen Plasma (FFP) and Others.

The global blood plasma derivatives market is segmented by type into several key categories: Factor VIII Concentrate, Factor IX Concentrate, Albumin, Immune Globulins, Anti-Thrombin III Concentrate, Fresh Frozen Plasma (FFP), and Others. Each segment plays a crucial role in addressing specific medical needs and contributes to the overall growth and diversification of the market.Factor VIII and Factor IX concentrates are essential in the management of hemophilia A and B, respectively. These products have revolutionized the treatment of bleeding disorders, allowing for better management and improved quality of life for patients. The increasing prevalence of hemophilia and advancements in recombinant technologies that enhance the safety and efficacy of these concentrates are driving their demand.

Albumin is a versatile plasma protein used in various medical applications, including volume expansion, shock treatment, and chronic liver conditions. Its broad therapeutic uses make it a critical component of the plasma derivatives market. The rising incidence of liver diseases and the growing use of albumin in critical care settings are significant factors propelling the market growth for this segment.Immune globulins, particularly intravenous immunoglobulin (IVIG), are extensively used to treat immune deficiencies, autoimmune diseases, and infections. The demand for immune globulins is surging due to the increasing prevalence of these conditions and the expanding therapeutic applications of these products. Ongoing research and development are further enhancing their efficacy, making them indispensable in modern medicine.

Anti-Thrombin III concentrate is vital for patients with hereditary anti-thrombin deficiency, which can lead to severe thrombotic events. The segment's growth is driven by the increasing recognition and diagnosis of this rare condition, coupled with the critical need for effective management options. The availability of advanced diagnostic tools has also contributed to the rising demand for Anti-Thrombin III concentrates.Fresh Frozen Plasma (FFP) is used in various therapeutic and surgical procedures, particularly in managing coagulation disorders and massive transfusions. Its immediate availability and broad applicability in emergency medicine make it a significant segment of the market. The "Others" category includes various niche plasma derivatives used in specialized treatments, further diversifying the market.

Global Blood Plasma Derivatives Market, Segmentation by Application

The Global Blood Plasma Derivatives Market has been segmented by Application into HIV, HemophiliaA, HemophiliaB, HepatitisB, HepatitisC, Bleedingdisorders, Hypogammaglobulinemia, ImmunodeficiencyDiseases and Others.

The global blood plasma derivatives market is segmented by application into several critical categories: HIV, Hemophilia A, Hemophilia B, Hepatitis B, Hepatitis C, Bleeding Disorders, Hypogammaglobulinemia, Immunodeficiency Diseases, and Others. This segmentation underscores the diverse therapeutic uses of plasma derivatives, each addressing specific medical conditions and contributing to the overall market growth.Blood plasma derivatives, particularly immune globulins, play a vital role in managing HIV. They help boost the immune system of patients with HIV, reducing the risk of infections and improving their quality of life. The increasing prevalence of HIV and ongoing efforts to enhance patient care through advanced treatments are driving demand in this segment.

Hemophilia A and B are among the most significant applications for plasma derivatives, specifically Factor VIII and Factor IX concentrates. These products are essential for preventing and treating bleeding episodes in hemophilia patients. The rising awareness, better diagnosis rates, and advancements in treatment protocols are key factors propelling the growth of these segments.Plasma-derived products are crucial in managing Hepatitis B and C, providing immunoglobulins that help prevent and treat these infections. The high global burden of hepatitis and the need for effective management strategies are driving the demand for plasma derivatives in these applications. The development of new therapeutic approaches and preventive measures also contributes to market growth.

Beyond hemophilia, plasma derivatives are extensively used to treat various other bleeding disorders. Products such as Fresh Frozen Plasma (FFP) and Anti-Thrombin III concentrates are vital in managing conditions like von Willebrand disease and other coagulopathies. The increasing prevalence of these disorders and the critical role of plasma derivatives in emergency and surgical care support the expansion of this segment.Hypogammaglobulinemia and other immunodeficiency diseases are key applications for immune globulins. These conditions require regular immunoglobulin replacement therapy to prevent infections and maintain immune function. The growing incidence of primary and secondary immunodeficiencies, coupled with advancements in treatment options, is driving the demand for plasma-derived immunoglobulins in this segment.

Global Blood Plasma Derivatives Market, Segmentation by End-Use

The Global Blood Plasma Derivatives Market has been segmented by End-Use into Hospitals & Clinics, Blood Transfusion Centers, Diagnostic Centers and Others.

The global blood plasma derivatives market is segmented by end-use into Hospitals & Clinics, Blood Transfusion Centers, Diagnostic Centers, and Others. This segmentation reflects the diverse settings in which plasma derivatives are utilized, each playing a crucial role in the delivery of these life-saving therapies and contributing to the overall market dynamics.Hospitals and clinics represent the largest end-use segment in the blood plasma derivatives market. These healthcare facilities are primary points of care where patients receive treatments for a wide range of conditions, including those managed by plasma derivatives such as hemophilia, immune deficiencies, and critical care scenarios. The increasing prevalence of chronic diseases, coupled with the rising number of surgical procedures and emergency cases, drives the demand for plasma-derived products in hospitals and clinics. Additionally, the integration of advanced medical technologies and the presence of specialized departments enhance the utilization of these therapies, making hospitals and clinics a vital segment for market growth.

Blood transfusion centers play a pivotal role in the collection, processing, and distribution of blood plasma. These centers are critical in ensuring a steady supply of plasma for fractionation into derivatives such as immunoglobulins, coagulation factors, and albumin. The growing network of blood donation drives and the implementation of stringent safety protocols have improved the efficiency and reliability of these centers. Furthermore, advancements in apheresis technology and better donor management systems have enhanced plasma collection processes, contributing significantly to the market's expansion. As awareness of the importance of blood and plasma donation increases, blood transfusion centers are expected to see a continued rise in activity and relevance.

Diagnostic centers are essential for the accurate diagnosis and monitoring of conditions that require plasma-derived therapies. These centers utilize advanced diagnostic tools and technologies to identify diseases such as hemophilia, immune deficiencies, and other bleeding disorders. Early and precise diagnosis is crucial for the effective management of these conditions, leading to timely intervention with appropriate plasma-derived products. The growing emphasis on preventive healthcare and the rising adoption of advanced diagnostic techniques are driving the demand for plasma derivatives in diagnostic centers. Additionally, the role of these centers in ongoing patient monitoring and follow-up care further underscores their importance in the market.

The "Others" category includes various healthcare settings such as homecare, research institutions, and specialized clinics that utilize plasma-derived products for specific therapeutic or research purposes. The rise in home-based care, facilitated by advancements in infusion technologies, allows patients to receive treatments such as immunoglobulin therapy in the comfort of their homes. Research institutions contribute to the development of new plasma-derived therapies and improvements in existing products, driving innovation in the market. Specialized clinics, focusing on particular conditions or patient groups, also play a significant role in the application of plasma derivatives. This diverse category highlights the expanding reach and application of plasma-derived products across different healthcare environments.

Global Blood Plasma Derivatives Market, Segmentation by Geography

In this report, the Global Blood Plasma Derivatives Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Blood Plasma Derivatives Market Share (%), by Geographical Region, 2024

North America holds the largest share of the global blood plasma derivatives market, driven by a well-established healthcare infrastructure, high healthcare expenditure, and significant support for blood donation programs. The United States, in particular, is a major contributor, with advanced medical facilities, extensive research and development activities, and a strong presence of key market players. The region's proactive approach to healthcare, combined with a high prevalence of chronic diseases and an aging population, further bolsters its market dominance.

Europe is the second-largest market for blood plasma derivatives, with substantial contributions from countries like Germany, France, and the United Kingdom. The region benefits from a robust healthcare system, extensive government support for medical research, and high awareness about plasma donation and its benefits. The prevalence of autoimmune and bleeding disorders in Europe necessitates a steady demand for plasma-derived products. Additionally, the presence of leading pharmaceutical companies and innovative research initiatives drive market growth in this region.

The Asia-Pacific region is poised for the fastest growth in the blood plasma derivatives market. Emerging economies such as China and India are at the forefront of this expansion, driven by increasing healthcare awareness, rising disposable incomes, and government initiatives to improve healthcare infrastructure. The growing prevalence of chronic and infectious diseases, coupled with improved access to healthcare services, is fueling demand for plasma derivatives. Investments in healthcare technology and the establishment of new plasma collection centers further enhance the market potential in this region.

Latin America holds a moderate share of the global market, with countries like Brazil and Mexico leading the way. The region's growth is supported by improving healthcare infrastructure, increased healthcare expenditure, and growing awareness about the therapeutic benefits of plasma derivatives. However, challenges such as limited access to advanced medical facilities and economic constraints can impact market growth. Nonetheless, ongoing efforts to enhance healthcare services and promote plasma donation are expected to drive steady growth in this region.

The Middle East & Africa region accounts for a smaller share of the global blood plasma derivatives market but is experiencing gradual growth. Key factors contributing to this growth include improving healthcare infrastructure, rising investments in healthcare, and increasing awareness about plasma-derived therapies. Countries such as Saudi Arabia, the UAE, and South Africa are making significant strides in healthcare development, which is expected to boost the demand for plasma derivatives. However, economic disparities and limited access to healthcare in some areas pose challenges to market expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Global Blood Plasma Derivatives Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers:

• Increasing Prevalence of Chronic Diseases
• Advancements in Medical Technology
• Rising Geriatric Population

• Growing Awareness and Adoption of Plasma-Derived Therapies - The growing awareness and adoption of plasma-derived therapies are significant drivers of the global blood plasma derivatives market. Over the past decade, there has been a concerted effort by healthcare providers, patient advocacy groups, and industry players to educate both the medical community and the general public about the benefits of plasma-derived products. These therapies are crucial in managing a range of medical conditions, including immunodeficiencies, autoimmune diseases, and bleeding disorders, which has underscored their importance in modern medicine.

  One of the key factors contributing to this increased awareness is the dissemination of information through various channels, including medical conferences, seminars, and awareness campaigns. These initiatives help in demystifying plasma-derived therapies, making them more accessible and understandable to both patients and healthcare practitioners. Additionally, success stories and case studies highlighting the efficacy of these therapies in improving patient outcomes have played a pivotal role in building trust and acceptance.

  The adoption of plasma-derived therapies is being accelerated by advancements in diagnostic technologies, which facilitate early and accurate diagnosis of conditions treatable with these products. This early diagnosis allows for timely intervention with plasma-derived therapies, improving patient prognosis and quality of life. The integration of these therapies into treatment protocols and guidelines by health authorities and professional medical associations also lends credibility and encourages their broader use.

  The ongoing improvements in the safety and efficacy of plasma-derived products, driven by rigorous research and development efforts, have bolstered confidence among healthcare providers. Innovations in plasma fractionation and purification techniques have significantly reduced the risk of transfusion-related complications, making these therapies safer for patients. This enhanced safety profile, coupled with proven clinical benefits, is fostering greater adoption across various healthcare settings.

Restraints:

• Supply Constraints and Donor Dependency
• High Costs of Plasma-Derived Therapies
• Regulatory and Compliance Challenges

• Risk of Transfusion-Transmitted Infections - The risk of transfusion-transmitted infections (TTIs) remains a significant restraint in the global blood plasma derivatives market. Despite advancements in screening and purification technologies, the potential for infections such as hepatitis B, hepatitis C, HIV, and other emerging pathogens continues to be a critical concern. This risk can deter both donors and recipients, impacting the overall supply and demand for plasma-derived products.

  One of the primary challenges is the window period of infections, during which the pathogen may be present in the donor's blood but not detectable by current screening methods. This gap can lead to the inadvertent transmission of infections through plasma-derived therapies. Although sophisticated nucleic acid testing (NAT) and other advanced screening techniques have significantly reduced this risk, no system is entirely foolproof. The possibility of new, unknown pathogens emerging further complicates the safety landscape.

  The process of plasma collection involves multiple donors, which increases the complexity of ensuring safety. Each batch of plasma-derived products is derived from pooled plasma of thousands of donors, raising the stakes for rigorous testing and quality control. The extensive and costly procedures required to mitigate TTIs, such as pathogen inactivation and advanced viral testing, can also impact the overall cost structure and availability of these therapies.

  Public perception and trust play a crucial role in the adoption of plasma-derived products. Historical instances of TTI outbreaks, although rare in recent times, have left a lasting impression on public consciousness. This lingering apprehension can influence patient and healthcare provider decisions, potentially limiting the market's growth. Efforts to rebuild and maintain trust through transparent communication, continuous monitoring, and prompt action in case of any safety concerns are essential.

Opportunties:

• Expansion in Emerging Markets
• Development of Novel Plasma-Derived Therapies
• Strategic Collaborations and Acquisitions

• Technological Innovations in Plasma Collection and Processing - Technological innovations in plasma collection and processing are driving significant advancements in the global blood plasma derivatives market. These innovations are enhancing the efficiency, safety, and scalability of plasma-derived products, addressing some of the critical challenges faced by the industry. One of the key areas of development is the improvement in plasma collection techniques, which now include automated apheresis machines. These machines enable the selective collection of plasma while returning other blood components to the donor, making the process quicker and less taxing on donors, thereby encouraging higher donation rates.

  Advancements in processing technologies have also revolutionized the plasma fractionation process, which is essential for extracting specific proteins and other valuable components from plasma. Modern fractionation techniques, such as cryoprecipitation and chromatographic purification, have significantly increased the yield and purity of plasma-derived products. These methods ensure that the final products are free from contaminants and have higher therapeutic efficacy. Moreover, innovations in viral inactivation and removal processes have enhanced the safety profile of these products by effectively eliminating pathogens, thus reducing the risk of transfusion-transmitted infections.

  Another notable innovation is the development of recombinant DNA technology and monoclonal antibody techniques, which have paved the way for the production of recombinant plasma proteins. These recombinant products mimic naturally occurring plasma proteins but are produced in controlled laboratory environments, ensuring consistent quality and reducing dependence on human donors. This shift not only addresses supply constraints but also opens new avenues for the treatment of rare and complex diseases.

  The integration of digital technologies and data analytics into plasma collection and processing is also transforming the market. Advanced data management systems and real-time monitoring tools are improving the efficiency of plasma collection centers by optimizing donor scheduling, ensuring regulatory compliance, and maintaining high standards of product quality. Additionally, blockchain technology is being explored to enhance traceability and transparency in the plasma supply chain, ensuring that every step from donation to final product delivery is securely documented and verifiable.

Key players in Global Blood Plasma Derivatives Market include:

• Baxter BioScience
• Grifols
• CSL Behring
• ViroPharma
• Talecris Biotherapeutics

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis